Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/124387
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Epperla, Narendranath | - |
dc.contributor.author | Ahn, Kwang Woo | - |
dc.contributor.author | Ahmed, Sairah | - |
dc.contributor.author | Jagasia, Madan | - |
dc.contributor.author | Digilio, Alyssa | - |
dc.contributor.author | Devine, Steven M. | - |
dc.contributor.author | Jaglowski, Samantha | - |
dc.contributor.author | Kennedy, Vanessa | - |
dc.contributor.author | Rezvani, Andrew R. | - |
dc.contributor.author | Smith, Sonali M. | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Fenske, Timothy S. | - |
dc.contributor.author | Kharfan-Dabaja, Mohamed A. | - |
dc.contributor.author | Armand, Philippe | - |
dc.contributor.author | Hamadani, Mehdi | - |
dc.date.accessioned | 2018-09-10T07:35:15Z | - |
dc.date.available | 2018-09-10T07:35:15Z | - |
dc.date.issued | 2017-06-12 | - |
dc.identifier.uri | http://hdl.handle.net/2445/124387 | - |
dc.description.abstract | Background: In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter studies comparing R-RIC and non-rituximab-containing reduced-intensity conditioning regimens (nonR-RIC) have not been performed. Using the CIBMTR database, we report the outcomes of R-RIC versus nonR-RIC regimens in B-NHL. Methods: We evaluated 1401 adult B-NHL patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) who received nonR-RIC (n = 1022) or R-RIC (n = 379) regimens. Graft-versus-host disease (GVHD) prophylaxis was limited to calcineurin inhibitor-based approaches. Results: Median follow-up of survivors in the R-RIC and nonR-RIC groups was 47 and 37 months, respectively. On multivariate analysis, no difference was seen between the R-RIC and nonR-RIC cohorts in terms of acute GVHD grade II-IV (RR = 1.14, 95% CI = 0.83-1.56, p = 0.43) or grade III-IV (RR = 1.16, 95% CI = 0.72-1.89, p = 0.54), chronic GVHD (RR = 1.15, 95% CI = 0.92-1.46, p = 0.22), non-relapse mortality (RR = 0.90; 95% CI = 0.67-1.22; p = 0.51), relapse/progression (RR = 0.79; 95% CI = 0.63-1.01; p = 0.055), and mortality (RR = 0.84, 95% CI = 0.69-1.02, p = 0.08) risk. However, R-RIC was associated with a significantly improved progression-free survival (RR = 0.76; 95% CI 0.62-0.92; p = 0.006). On subgroup analysis, mortality benefit was noted in the R-RIC group patients not receiving busulfanbased RIC (RR = 0.76; 95% CI = 0.60-0.96; p = 0.02) and with the use of a higher cumulative rituximab dose (RR = 0.43; 95% CI = 0.21-0.90; p = 0.02). Conclusion: Our analysis shows that inclusion of rituximab in RIC regimens improves progression-free survival in patients with B cell NHL. These data supports the use of R-RIC in B-NHL patients undergoing allo-HCT. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s13045-017-0487-y | - |
dc.relation.ispartof | Journal of Hematology & Oncology, 2017, vol. 10, num. 117 | - |
dc.relation.uri | https://doi.org/10.1186/s13045-017-0487-y | - |
dc.rights | cc by (c) Epperla et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Malaltia de Hodgkin | - |
dc.subject.classification | Anticossos monoclonals | - |
dc.subject.other | Hodgkin's disease | - |
dc.subject.other | Monoclonal antibodies | - |
dc.title | Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2018-07-24T12:05:55Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28606176 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
EpperlaN.pdf | 545.7 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License